...
首页> 外文期刊>Journal of proteome research >New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics
【24h】

New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics

机译:针对蛋白激酶组蛋白激酶抑制剂选择性分析的靶向VEGF受体的新亲和探针

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Solid tumors are dependent for growth on nutrients and the supply of oxygen, which they often acquire via neoangiogenesis. Vascular endothelial growth factors and the corresponding receptors (VEGFRs) play central roles in this process, and consequently, the blockade of this pathway is one therapeutic strategy for cancer treatment. A number of small molecules inhibiting VEGFR inhibitors have been developed for clinical use, and a comprehensive view of target selectivity is important to assess the therapeutic as well as risk potential of a drug molecule. Recent advances in mass spectrometry-based chemical proteomics allow analyses of drug-target interactions under close-to-physiological conditions, and in this study, we report on the design, synthesis, and application of a small molecule affinity probe as a tool for the selectivity profiling of VEGFR and other kinase inhibitors. The probe is capable of binding >132 protein kinases, including angiokinases such as VEGFRs, PDGFRs, and c-KIT from lysates of cancer cell lines or human placenta tissue. Combining the new probe with Kinobeads in competitive binding assays, we were able to identify nanomolar off-targets of the VEGFR/PDGFR inhibitors pazopanib and axitinib. Because of its broad binding spectrum, the developed chemical tool can be generically used for the discovery of kinase inhibitor targets, which may contribute to a more comprehensive understanding of the mechanisms of action of such drugs.
机译:实体瘤的生长依赖营养物和氧气的供应,而营养物和氧气的供应通常是通过新血管生成获得的。血管内皮生长因子和相应的受体(VEGFRs)在此过程中起着核心作用,因此,阻断该途径是癌症治疗的一种治疗策略。已经开发出许多抑制VEGFR抑制剂的小分子用于临床,靶标选择性的全面观点对于评估药物分子的治疗和潜在风险很重要。基于质谱的化学蛋白质组学的最新进展允许在接近生理条件下分析药物-靶标之间的相互作用,在本研究中,我们报告了小分子亲和探针作为该工具的设计,合成和应用。 VEGFR和其他激酶抑制剂的选择性分析。该探针能够结合> 132种蛋白激酶,包括来自癌细胞系或人胎盘组织裂解物的血管激酶,如VEGFR,PDGFR和c-KIT。在竞争性结合试验中将新探针与Kinobeads结合使用,我们能够鉴定出VEGFR / PDGFR抑制剂pazopanib和axitinib的纳摩尔脱靶。由于其广泛的结合谱,可以将开发的化学工具广泛用于发现激酶抑制剂靶标,这可能有助于更全面地了解此类药物的作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号